Top Page
PYC Therapeutics Limited
(Sydney:PYC)
PYC Therapeutics Limited (PYC) vs. iShares MSCI Australia ETF (EWA)
PYC Therapeutics Limited Business Overview & Revenue Model
PYC Therapeutics Limited Financial Statement Overview
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 23.49M | 23.49M | 22.06M | 15.81M | 16.04M | 3.07M |
| Gross Profit | 23.49M | 23.49M | 22.06M | 14.92M | 15.20M | 2.45M |
| EBITDA | -52.88M | -52.88M | -54.55M | -38.25M | -29.39M | -21.04M |
| Net Income | -50.30M | -50.30M | -37.73M | -22.79M | -13.86M | -17.77M |
Balance Sheet | ||||||
| Total Assets | 183.28M | 183.28M | 91.24M | 37.17M | 45.35M | 57.94M |
| Cash, Cash Equivalents and Short-Term Investments | 153.05M | 153.05M | 66.87M | 15.57M | 29.11M | 51.50M |
| Total Debt | 1.02M | 1.02M | 1.11M | 315.49K | 943.77K | 730.35K |
| Total Liabilities | 13.27M | 13.27M | 10.18M | 8.72M | 5.15M | 4.02M |
| Stockholders Equity | 169.57M | 169.57M | 80.50M | 27.75M | 39.35M | 53.04M |
Cash Flow | ||||||
| Free Cash Flow | -52.54M | -52.54M | -38.90M | -24.91M | -22.17M | -12.38M |
| Operating Cash Flow | -51.56M | -51.56M | -38.59M | -24.42M | -21.78M | -11.79M |
| Investing Cash Flow | -975.40K | -975.40K | -307.04K | -477.12K | 32.68M | -15.52M |
| Financing Cash Flow | 138.66M | 138.66M | 90.19M | 11.44M | -182.36K | 38.56M |
PYC Therapeutics Limited Technical Analysis
PYC Therapeutics Limited Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
73 Outperform | AU$549.20M | 15.14 | 15.90% | 0.38% | 7.76% | 1.55% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | AU$911.34M | -15.97 | -40.23% | ― | ― | -5.70% | |
49 Neutral | AU$596.86M | -9.48 | -35.86% | ― | ― | -19.21% | |
47 Neutral | AU$197.01M | -2.24 | -90.93% | ― | 456.50% | -457.14% | |
46 Neutral | AU$1.15B | -14.73 | -54.37% | ― | ― | -29.93% | |
42 Neutral | AU$738.77M | -2.95 | ― | ― | -80.08% | 59.91% |
PYC Therapeutics Limited Corporate Events
In its fourth-quarter 2025 update, PYC Therapeutics reported continued progress across all four of its pipeline programs, highlighting key clinical milestones and positioning the company for important safety and efficacy read-outs over the next two years. The company established a favourable safety and tolerability profile for its polycystic kidney disease candidate in healthy volunteers, clearing the way for progression to patient studies; advanced its autosomal dominant optic atrophy program into a global repeat-dose trial aimed at demonstrating clinical proof of concept; presented longer-term data showing sustained vision improvement in patients with retinitis pigmentosa type 11 treated with its investigational therapy; and showcased preclinical data, including non-human primate results, to support moving its Phelan-McDermid syndrome candidate into clinical trials. Collectively, these developments underscore PYC’s execution against its clinical roadmap and strengthen its positioning as an emerging player in RNA therapeutics for high-unmet-need genetic diseases.
The most recent analyst rating on (AU:PYC) stock is a Hold with a A$1.50 price target. To see the full list of analyst forecasts on PYC Therapeutics Limited stock, see the AU:PYC Stock Forecast page.
PYC Therapeutics has proposed, subject to shareholder approval, the issuance of 1.5 million unlisted options to managing director Dr Rohan Hockings under its Long Term Incentive Plan, with a four-year expiry, growth-oriented exercise price of $2.52 and staged vesting over 12 and 24 months. The board says the move follows a broader review of retention incentives for key personnel driving the company’s RNA therapy pipeline and is designed to align Hockings’ remuneration with shareholder value creation and the rigorous governance and execution standards required as PYC advances its precision medicine programs.
The most recent analyst rating on (AU:PYC) stock is a Buy with a A$2.85 price target. To see the full list of analyst forecasts on PYC Therapeutics Limited stock, see the AU:PYC Stock Forecast page.
PYC Therapeutics Limited has issued an updated notification to the ASX correcting a typographical error in a previously lodged Appendix 3G relating to unquoted equity securities. The company clarified that the option strike price for the relevant securities is A$2.52 per option rather than A$2.25 as originally recorded on 6 January 2026, a change that ensures accurate disclosure of the terms of its equity instruments for investors and other stakeholders but does not represent a new capital raising or change in overall financing strategy.
The most recent analyst rating on (AU:PYC) stock is a Buy with a A$2.85 price target. To see the full list of analyst forecasts on PYC Therapeutics Limited stock, see the AU:PYC Stock Forecast page.
PYC Therapeutics has released an updated corporate presentation timed with its participation at the 44th annual JP Morgan Healthcare Conference in San Francisco, underscoring its ongoing efforts to position itself among leading players in the RNA therapeutics field. By showcasing its precision RNA medicines pipeline and delivery platform at a major global healthcare investor forum, the company is seeking to raise its profile with investors and strategic partners, potentially supporting future funding, collaborations and advancement of its clinical programs for underserved genetic disease patients.
The most recent analyst rating on (AU:PYC) stock is a Buy with a A$2.85 price target. To see the full list of analyst forecasts on PYC Therapeutics Limited stock, see the AU:PYC Stock Forecast page.
PYC Therapeutics has proposed, subject to shareholder approval, the issuance of 1,000,000 unlisted options to director Professor Ian Constable under its Long Term Incentive Plan, matching the vesting conditions and A$1.80 strike price of options previously granted to its chairman upon appointment. The move, detailed alongside a Change of Director Interest Notice, underscores the company’s continued use of equity-based incentives to align board members with long-term shareholder value as it advances its RNA therapy pipeline for genetic diseases.
The most recent analyst rating on (AU:PYC) stock is a Buy with a A$2.85 price target. To see the full list of analyst forecasts on PYC Therapeutics Limited stock, see the AU:PYC Stock Forecast page.
PYC Therapeutics Limited has issued 2.5 million unlisted employee options under its employee incentive scheme, effective 5 January 2026. The unquoted options are not intended to be listed on the ASX and form part of the company’s broader strategy to retain and incentivise key personnel, signalling continued reliance on equity-based compensation to support its development pipeline and align employees with future growth objectives.
The most recent analyst rating on (AU:PYC) stock is a Buy with a A$2.85 price target. To see the full list of analyst forecasts on PYC Therapeutics Limited stock, see the AU:PYC Stock Forecast page.
PYC Therapeutics has granted 2.5 million unlisted options to senior employees under its Long Term Incentive Plan, aiming to better align staff incentives with shareholder interests ahead of a series of key human clinical data read-outs expected in 2026. The move underscores the company’s focus on retaining and motivating key talent as it approaches potentially value-defining milestones in its precision RNA medicine programs, signalling an effort to strengthen internal commitment during a pivotal year for its clinical and commercial trajectory.
The most recent analyst rating on (AU:PYC) stock is a Buy with a A$2.85 price target. To see the full list of analyst forecasts on PYC Therapeutics Limited stock, see the AU:PYC Stock Forecast page.
PYC Therapeutics Limited has disclosed a change in director Peter Coleman’s interests, reporting the issue of 2,000,000 unlisted options as part of his remuneration. The options, granted pursuant to his letter of appointment, carry an exercise price of $1.80 and expire on 19 November 2028, marking Coleman’s first holding of these securities and signalling the company’s use of equity-based incentives to align director compensation with shareholder value.
The most recent analyst rating on (AU:PYC) stock is a Buy with a A$2.85 price target. To see the full list of analyst forecasts on PYC Therapeutics Limited stock, see the AU:PYC Stock Forecast page.
PYC Therapeutics Limited has notified the market that it will issue 2,000,000 unlisted options as unquoted equity securities, effective 23 December 2025. The creation of this new class of unlisted options indicates the company is using equity-based instruments, likely for capital management or incentive purposes, which may affect ownership structure and align stakeholders’ interests with the company’s longer-term performance.
The most recent analyst rating on (AU:PYC) stock is a Buy with a A$2.85 price target. To see the full list of analyst forecasts on PYC Therapeutics Limited stock, see the AU:PYC Stock Forecast page.
PYC Therapeutics has issued 2,000,000 unlisted options to director Peter Coleman under an exception to ASX Listing Rule 10.12, with associated terms and conditions and regulatory notices to be filed. The move underscores the company’s use of equity-based incentives in its governance and remuneration framework as it advances its clinical-stage RNA therapeutic programs for genetic diseases.
The most recent analyst rating on (AU:PYC) stock is a Buy with a A$2.85 price target. To see the full list of analyst forecasts on PYC Therapeutics Limited stock, see the AU:PYC Stock Forecast page.
PYC Therapeutics announced positive safety outcomes from Part A of its Phase 1a/1b single-ascending-dose clinical trial of PYC-003, reporting that single doses up to 4 mg/kg in healthy volunteers were safe and well tolerated with no treatment-emergent serious adverse events. Based on these data, the company has begun dosing PKD patients in Part B of the study at 1.2 mg/kg and is preparing to initiate a repeat-dose Part C in the first half of 2026, positioning PYC-003 to progress into a planned single registrational Phase 2/3 trial aimed at supporting a future new drug application and advancing its strategy in the PKD treatment landscape.
The most recent analyst rating on (AU:PYC) stock is a Buy with a A$2.85 price target. To see the full list of analyst forecasts on PYC Therapeutics Limited stock, see the AU:PYC Stock Forecast page.
PYC Therapeutics Limited announced a change in the director’s interest as Dr. Rohan Hockings acquired 133,350 ordinary shares through an on-market purchase valued at $200,003. This acquisition reflects a significant personal investment by the director, potentially indicating confidence in the company’s future prospects and strategic direction.
The most recent analyst rating on (AU:PYC) stock is a Hold with a A$1.50 price target. To see the full list of analyst forecasts on PYC Therapeutics Limited stock, see the AU:PYC Stock Forecast page.
PYC Therapeutics Limited has received approval from the Safety Review Committee to escalate dosing in the clinical trial of its drug candidate PYC-003 for Polycystic Kidney Disease. This approval marks a significant step in the Single Ascending Dose study, allowing the company to proceed to the second cohort, and is part of a broader strategy to advance towards a registrational trial aimed at supporting a New Drug Application.
The most recent analyst rating on (AU:PYC) stock is a Hold with a A$1.50 price target. To see the full list of analyst forecasts on PYC Therapeutics Limited stock, see the AU:PYC Stock Forecast page.
PYC Therapeutics Limited announced changes in its board of directors, with Peter Coleman being appointed as a new director and Alan Tribe concluding his directorship. These changes may impact the company’s strategic direction and governance, potentially influencing its operations and stakeholder interests.
The most recent analyst rating on (AU:PYC) stock is a Hold with a A$1.50 price target. To see the full list of analyst forecasts on PYC Therapeutics Limited stock, see the AU:PYC Stock Forecast page.
PYC Therapeutics Limited announced the results of its Annual General Meeting, where Resolutions 1 and 3 were passed, while Resolution 2 was withdrawn. The approval of these resolutions reflects the company’s ongoing governance and strategic direction, potentially impacting its operations and industry positioning.
The most recent analyst rating on (AU:PYC) stock is a Hold with a A$1.50 price target. To see the full list of analyst forecasts on PYC Therapeutics Limited stock, see the AU:PYC Stock Forecast page.
PYC Therapeutics Limited has provided an update on its business operations, emphasizing its drug development pipeline. The company’s investigational drug candidates are still under development and have not received regulatory approval, highlighting the ongoing risks and uncertainties in its operations.
The most recent analyst rating on (AU:PYC) stock is a Hold with a A$1.50 price target. To see the full list of analyst forecasts on PYC Therapeutics Limited stock, see the AU:PYC Stock Forecast page.
PYC Therapeutics Limited has announced promising results from its ongoing Phase 1/2 clinical trials of VP-001, an investigational drug candidate for Retinitis Pigmentosa type 11 (RP11). Patients treated with VP-001 have shown sustained improvements in vision and retinal sensitivity up to 18 months post-treatment, with the treated eyes outperforming untreated eyes and a natural history control group across all measured endpoints. The drug has demonstrated a favorable safety profile with no serious adverse events reported, and PYC is preparing to engage with the US FDA to design a registrational trial expected to commence in 2026.
The most recent analyst rating on (AU:PYC) stock is a Hold with a A$1.50 price target. To see the full list of analyst forecasts on PYC Therapeutics Limited stock, see the AU:PYC Stock Forecast page.
PYC Therapeutics Limited has announced the appointment of Peter Coleman as the new Independent Non-Executive Chair, effective after the 2025 Annual General Meeting. This leadership change is part of a broader board renewal process, with current Chair Alan Tribe stepping down. Coleman, with a background in corporate governance and mergers, is expected to guide PYC through its next growth phase, potentially opening new commercial avenues. The company is also undergoing changes in its executive team, with Andrew Taylor resigning as co-Company Secretary and CFO, while Kevin Hart will continue as the sole Company Secretary. These strategic shifts aim to align with long-term shareholder value creation and strengthen PYC’s position in the RNA therapy market.
The most recent analyst rating on (AU:PYC) stock is a Hold with a A$1.50 price target. To see the full list of analyst forecasts on PYC Therapeutics Limited stock, see the AU:PYC Stock Forecast page.
PYC Therapeutics Limited has announced that its Annual General Meeting will be held on November 18, 2025, at the Harry Perkins Institute of Medical Research in Western Australia. The meeting will be accessible both in-person and via Zoom, allowing shareholders to participate remotely, which reflects the company’s commitment to engaging with its stakeholders and maintaining transparency in its operations.
The most recent analyst rating on (AU:PYC) stock is a Hold with a A$1.50 price target. To see the full list of analyst forecasts on PYC Therapeutics Limited stock, see the AU:PYC Stock Forecast page.